The purpose of the study is to evaluate how safe and effective Isavuconazonium sulfate is for paediatric patients (children). The study will also look at the way the body takes up, uses and breaks down and removes the study medicine. This is important because it will help determine how the study medicine may be used safely in children and adolescents with as few side effects as possible.

Duration of study

You may have to return to the hospital, or the study doctor might call you by phone, 30 and 60 days after your child’s last dose of study medicine to see if there have been any changes in your child’s medication.

Sponsor and Funder

Astellas Pharma Global Development Inc. (APGD)

Population (age group)

1 year to less than 18 years old